Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mynflu002
- Development stage
- Preclinical
- Lead developer
- Mynvax
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Mynflu002 is a preclinical-stage recombinant protein subunit vaccine being developed by Mynvax for the prevention of influenza. The vaccine is designed to be multivalent and adjuvanted, targeting the hemagglutinin (HA) protein and other conserved antigens specifically from H1 and H3 influenza strains. By focusing on conserved regions of the influenza virus, Mynflu002 aims to provide broader and more durable protection compared to traditional seasonal flu vaccines, potentially reducing the need for frequent strain updates.
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Mynflu002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mynflu002.